LIXT vs. BCDA, BCTX, OMGA, ACXP, MYNZ, SNSE, TXMD, FLGC, PMCB, and CHRO
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include BioCardia (BCDA), BriaCell Therapeutics (BCTX), Omega Therapeutics (OMGA), Acurx Pharmaceuticals (ACXP), Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), Flora Growth (FLGC), PharmaCyte Biotech (PMCB), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry.
Lixte Biotechnology vs.
Lixte Biotechnology (NASDAQ:LIXT) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 14.8% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BioCardia has a consensus price target of $25.00, indicating a potential upside of 982.25%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Lixte Biotechnology.
BioCardia received 17 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
In the previous week, Lixte Biotechnology's average media sentiment score of 0.00 equaled BioCardia'saverage media sentiment score.
Lixte Biotechnology has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Lixte Biotechnology's return on equity.
Lixte Biotechnology has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Lixte Biotechnology has higher earnings, but lower revenue than BioCardia. Lixte Biotechnology is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Summary
BioCardia beats Lixte Biotechnology on 11 of the 15 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:LIXT) was last updated on 2/22/2025 by MarketBeat.com Staff
